CIK 0001628171
- Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472029180
- Phone
- +1 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $59,991,980
- in 20 filings, $60.0M under 10b5-1 plans
Net −$59,991,980. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 82 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-16 | Kelsey Stephen Michael | Exercise or conversion 10b5-1 | +27,160 | $18.56 | $504K | 313,467 |
| 2026-11-16 | Kelsey Stephen Michael | Sale 10b5-1 | −11,542 | $166.75 | $1.9M | 301,925 |
| 2026-11-16 | Kelsey Stephen Michael | Sale 10b5-1 | −3,627 | $167.66 | $608K | 298,298 |
| 2026-11-16 | Kelsey Stephen Michael | Sale 10b5-1 | −8,039 | $168.64 | $1.4M | 290,259 |
| 2026-11-16 | Kelsey Stephen Michael | Sale 10b5-1 | −3,052 | $169.46 | $517K | 287,207 |
| 2026-11-16 | Kelsey Stephen Michael | Sale 10b5-1 | −700 | $170.40 | $119K | 286,507 |
| 2026-11-16 | Kelsey Stephen Michael | Sale 10b5-1 | −200 | $171.65 | $34K | 286,307 |
| 2026-11-16 | Kelsey Stephen Michael | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −27,160 | 108,640 | ||
| 2026-11-13 | Borellini Flavia Director | Exercise or conversion | +2,500 | $37.54 | $94K | 28,715 |
| 2026-11-13 | Borellini Flavia Director | Exercise or conversion · Stock Option (Right to Buy) | −2,500 | 13,455 | ||
| 2026-11-11 | Anders Jack Chief Financial Officer | Exercise or conversion 10b5-1 | +15,900 | $42.45 | $675K | 135,116 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Exercise or conversion 10b5-1 | +19,850 | $18.56 | $368K | 154,966 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −3,499 | $181.04 | $633K | 151,467 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −5,776 | $182.09 | $1.1M | 145,691 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −2,700 | $182.87 | $494K | 142,991 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −1,900 | $184.02 | $350K | 141,091 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −800 | $185.04 | $148K | 140,291 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −400 | $186.41 | $75K | 139,891 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −600 | $187.34 | $112K | 139,291 |
| 2026-11-11 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −200 | $189.17 | $38K | 139,091 |
Page 1 of 39 · 775 trades